Carfilzomib for relapsed or refractory multiple myeloma

Tetsuya Tanimoto¹, Kenji Tsuda², Kumi Oshima³, Jinichi Mori³, Hiroaki Shimmura³

Affiliations

¹ Jyoban Hospital of Tokiwa Foundation, Fukushima 9728322, Japan. Electronic address: tetanimot@yahoo.co.jp.
² Teikyo University Chiba Medical Center, Chiba, Japan.
³ Jyoban Hospital of Tokiwa Foundation, Fukushima 9728322, Japan.

PMID: 29304356
DOI: 10.1016/S1470-2045(17)30859-8

Comment

Carfilzomib for relapsed or refractory multiple myeloma

Tetsuya Tanimoto et al. Lancet Oncol. 2018 Jan.

. 2018 Jan;19(1):e1.

doi: 10.1016/S1470-2045(17)30859-8.

Authors

Tetsuya Tanimoto¹, Kenji Tsuda², Kumi Oshima³, Jinichi Mori³, Hiroaki Shimmura³

Affiliations

¹ Jyoban Hospital of Tokiwa Foundation, Fukushima 9728322, Japan. Electronic address: tetanimot@yahoo.co.jp.
² Teikyo University Chiba Medical Center, Chiba, Japan.
³ Jyoban Hospital of Tokiwa Foundation, Fukushima 9728322, Japan.

PMID: 29304356
DOI: 10.1016/S1470-2045(17)30859-8

No abstract available

PubMed Disclaimer

Comment in

Carfilzomib for relapsed or refractory multiple myeloma - Authors' reply.
Dimopoulos MA, Kimball AS. Dimopoulos MA, et al. Lancet Oncol. 2018 Jan;19(1):e2. doi: 10.1016/S1470-2045(17)30920-8. Lancet Oncol. 2018. PMID: 29304357 No abstract available.

Comment on

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, Orlowski RZ, Ludwig H, Facon T, Hajek R, Weisel K, Hungria V, Minuk L, Feng S, Zahlten-Kumeli A, Kimball AS, Moreau P. Dimopoulos MA, et al. Lancet Oncol. 2017 Oct;18(10):1327-1337. doi: 10.1016/S1470-2045(17)30578-8. Epub 2017 Aug 23. Lancet Oncol. 2017. PMID: 28843768 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Carfilzomib for relapsed or refractory multiple myeloma

Affiliations

Carfilzomib for relapsed or refractory multiple myeloma

Authors

Affiliations

Comment in

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical